FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

Share this content:
Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.
Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.

Regorafenib, a multikinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC) after prior sorafenib therapy.1

Regorafenib is also approved for the treatment of relapsed/refractory colorectal cancer and gastrointestinal stromal tumors. Priority Review designation was granted to regorafenib for this indication, and it was assigned an Orphan Drug designation.

The approval was based on a randomized controlled trial of 573 patients with HCC who had progressed after sorafenib.

Regorafenib increased median overall survival to 10.6 months from 7.8 months with placebo. The median progression-free survival was also prolonged with regorafenib (3.1 months) compared with placebo (1.5 months).

The response rate was 11% with regorafenib and 4% with placebo.

RELATED: Clinical Pathways: A Cost-effective System for Determining mCRC Treatment

The adverse events associated with regorafenib are similar to other multikinase inhibitors and include gastrointestinal and abdominal pain, hand-foot skin reaction, fatigue, diarrhea, and hypertension.

Reference

  1. FDA expands approved use of Stivarga to treat liver cancer [news release]. Silver Spring, MD: US Food and Drug Administration; April 27, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed April 27, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters